Your browser doesn't support javascript.
loading
Chemotherapy for Muscle-invasive Bladder Cancer: Impact of Cisplatin Delivery on Renal Function and Local Control Rate in the Randomized Phase III VESPER (GETUG-AFU V05) Trial.
Culine, Stéphane; Harter, Valentin; Gravis, Gwenaelle; Fléchon, Aude; Chevreau, Christine; Mahammedi, Hakim; Laguerre, Brigitte; Guillot, Aline; Joly, Florence; Abadie-Lacourtoisie, Sophie; Geoffrois, Lionnel; Fiore, Frédéric Di; Roubaud, Guilhem; Barthélémy, Philippe; Voog, Eric; Emambux, Sheik; Serrate, Camille; Saldana, Carolina; Nguyen-Tan-Hon, Thierry; Loriot, Yohann; Eymard, Jean-Christophe; Huillard, Olivier; Rolland, Frédéric; Houédé, Nadine; Spano, Jean-Philippe; Demery, Mounira El; Vieillot, Sabine; L'Haridon, Tifenn; Hilgers, Werner; Allory, Yves; Pfister, Christian.
Afiliación
  • Culine S; Department of Medical Oncology, Saint-Louis Hospital, AP-HP, Faculté de Paris, France. Electronic address: stephane.culine@aphp.fr.
  • Harter V; North-West Canceropole Data Center, Baclesse Cancer Center, Caen, France.
  • Gravis G; Department of Medical Oncology, Paoli-Calmette Institute, Marseille, France.
  • Fléchon A; Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
  • Chevreau C; Department of Medical Oncology, ICR-IUCT Oncopole, Toulouse, France.
  • Mahammedi H; Department of Medical Oncology, Jean Perrin Cancer Center, Clermont-Ferrand, France.
  • Laguerre B; Department of Medical Oncology, Eugène Marquis Cancer Center, Rennes, France.
  • Guillot A; Department of Medical Oncology, Lucien Neuwirth Cancer Institute, St Priest en Jarez, France.
  • Joly F; Department of Medical Oncology, Baclesse Cancer Center, Caen, France.
  • Abadie-Lacourtoisie S; Department of Medical Oncology, Institut de cancérologie de l'Ouest, Angers, France.
  • Geoffrois L; Department of Medical Oncology, Lorraine-Alexis Vautrin Cancer Institute, Nancy, France.
  • Fiore FD; Digestive and uro-oncology Unit, Charles Nicolle University Hospital, Rouen, France.
  • Roubaud G; Department of Medical Oncology, Bergonié Institute, Bordeaux, France.
  • Barthélémy P; Department of Medical Oncology, University Hospital, Strasbourg, France.
  • Voog E; Victor Hugo Clinic, Le Mans, France.
  • Emambux S; Department of Medical Oncology, University Hospital, Poitiers, France.
  • Serrate C; Department of Medical Oncology, Diaconesses Croix Saint-Simon Hospital, Paris, France.
  • Saldana C; Department of Medical Oncology, Henri Mondor University Hospital, AP-HP, Créteil, France.
  • Nguyen-Tan-Hon T; Department of Medical Oncology, University Hospital, Besançon, France.
  • Loriot Y; Department of Cancer Medicine, Gustave Roussy, Inserm U981, Villejuif, France.
  • Eymard JC; Department of Medical Oncology, Jean Godinot Institute, Reims, France.
  • Huillard O; Department of Medical Oncology, Cochin Port-Royal University Hospital, AP-HP Centre, Paris, France.
  • Rolland F; Department of Medical Oncology, West County Cancer Institute, Nantes, France.
  • Houédé N; Gard Cancer Institute, University Hospital, Nîmes, Inserm U1194 Montpellier Cancer Institute, Montpellier University, Nimes, France.
  • Spano JP; Department of Medical Oncology, Pitié Salpétrière University Hospital, AP-HP-SU, IUC, Paris, France.
  • Demery ME; Department of Oncology, Cap d'Or Clinic, La Seyne sur Mer, France.
  • Vieillot S; Department of Oncology, Saint-Pierre Clinic, Perpignan, France.
  • L'Haridon T; Department of Medical Oncology, Vendée Regional Hospital, La Roche-sur-Yon, France.
  • Hilgers W; Uro-Oncology Unit, Sainte Catherine Institute, Avignon, France.
  • Allory Y; Department of Pathology, Curie Institute, Saint-Cloud, France.
  • Pfister C; Department of Urology and Clinical Investigation Center, Inserm 1404, Charles Nicolle University Hospital, Rouen, France.
Clin Genitourin Cancer ; 19(6): 554-562, 2021 12.
Article en En | MEDLINE | ID: mdl-34602349
BACKGROUND: Cisplatin-based combination chemotherapy before surgery is the standard of care for muscle-invasive bladder cancer. However, the optimal chemotherapy modalities have not been precisely defined to date. PATIENTS AND METHODS: In the VESPER trial, patients received after randomization either gemcitabine and cisplatin (GC, 4 cycles) or methotrexate, vinblastine, doxorubicin and cisplatin (dose dense [dd]-MVAC, 6 cycles). Creatinine clearance (CrCl) was calculated before each cycle according to the Cockroft and Gault formula. Definition criteria for local control after neoadjuvant chemotherapy included pathological complete response (ypT0N0), pathological downstaging (
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Cisplatino Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clin Genitourin Cancer Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2021 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias de la Vejiga Urinaria / Cisplatino Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Clin Genitourin Cancer Asunto de la revista: NEOPLASIAS / UROLOGIA Año: 2021 Tipo del documento: Article